Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)

Summit Therapeutics' Notes Payables history spans 4 years, with the latest figure at $24.5 million for Q3 2024.

  • For Q3 2024, Notes Payables fell 75.5% year-over-year to $24.5 million; the TTM value through Sep 2024 reached $24.5 million, down 75.5%, while the annual FY2022 figure was $19.8 million, N/A changed from the prior year.
  • Notes Payables reached $24.5 million in Q3 2024 per SMMT's latest filing, down from $100.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $100.0 million in Q3 2023 to a low of $19.8 million in Q4 2022.
  • Average Notes Payables over 4 years is $59.8 million, with a median of $55.0 million recorded in 2021.
  • The largest YoY upside for Notes Payables was 75.5% in 2024 against a maximum downside of 75.5% in 2024.
  • A 4-year view of Notes Payables shows it stood at $55.0 million in 2021, then crashed by 64.03% to $19.8 million in 2022, then surged by 405.82% to $100.0 million in 2023, then plummeted by 75.5% to $24.5 million in 2024.
  • Per Business Quant, the three most recent readings for SMMT's Notes Payables are $24.5 million (Q3 2024), $100.0 million (Q2 2024), and $100.0 million (Q3 2023).